Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -11.05% is 58% above its 5-year average of -26.23%, near the high end of its 5-year range (-35.63%–-11.05%).
42.88% above its 12-month average of -19.34%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -3.34%.
RETURN ON ASSETS (ROA)
-11.05%
RETURN ON ASSETS (ROA) AVG TTM
-19.34%
RETURN ON ASSETS (ROA) AVG 3Y
-25.88%
RETURN ON ASSETS (ROA) AVG 5Y
-26.23%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+42.88%
CURRENT VS 3Y AVG
+57.31%
CURRENT VS 5Y AVG
+57.88%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+65.73%
vs the sector median at left
Establishment Labs Holdings Inc.
Market Cap
$1.92B
Return on Assets (ROA)
-11.05%
TTM Avg
-19.34%
3Y Avg
-25.88%
5Y Avg
-26.23%
Market Cap
$1.91B
Return on Assets (ROA)
-37.11%
TTM Avg
4.34%
3Y Avg
-11.90%
5Y Avg
4.27%
Market Cap
$1.91B
Return on Assets (ROA)
-15.46%
TTM Avg
-32.65%
3Y Avg
-30.38%
5Y Avg
-46.54%
Market Cap
$1.90B
Return on Assets (ROA)
-44.98%
TTM Avg
-76.52%
3Y Avg
-94.59%
5Y Avg
-76.85%
Market Cap
$1.89B
Return on Assets (ROA)
-37.78%
TTM Avg
-24.95%
3Y Avg
-12.79%
5Y Avg
-23.19%
Market Cap
$1.95B
Return on Assets (ROA)
-52.34%
TTM Avg
-54.87%
3Y Avg
-41.09%
5Y Avg
-94.89%
Market Cap
$1.96B
Return on Assets (ROA)
-11.00%
TTM Avg
-5.98%
3Y Avg
-9.46%
5Y Avg
-10.43%
Market Cap
$1.89B
Return on Assets (ROA)
11.27%
TTM Avg
-4.02%
3Y Avg
-13.89%
5Y Avg
-9.34%
Market Cap
$1.97B
Return on Assets (ROA)
-20.72%
TTM Avg
-40.50%
3Y Avg
-23.66%
5Y Avg
-16.68%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Establishment Labs Holdings Inc. (ESTA) | $1.92B | -11.05% | -19.34% | -25.88% | -26.23% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.91B | -37.11% | 4.34% | -11.90% | 4.27% |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.91B | -15.46% | -32.65% | -30.38% | -46.54% |
| Immunome, Inc. (IMNM)vs › | $1.90B | -44.98% | -76.52% | -94.59% | -76.85% |
| Zymeworks Inc. (ZYME)vs › | $1.89B | -37.78% | -24.95% | -12.79% | -23.19% |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $1.95B | -52.34% | -54.87% | -41.09% | -94.89% |
| AxoGen, Inc. (AXGN)vs › | $1.96B | -11.00% | -5.98% | -9.46% | -10.43% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 11.27% | -4.02% | -13.89% | -9.34% |
| Vir Biotechnology, Inc. (VIR)vs › | $1.97B | -20.72% | -40.50% | -23.66% | -16.68% |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.97B | 14.58% | 11.33% | 2.89% | -3.84% |
ROA
-11.1%
ROE
-180.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -14.30% |
| 2024-12-31 | -24.39% |
| 2023-12-31 | -29.22% |
| 2022-12-31 | -35.63% |
| 2021-12-31 | -29.48% |
| 2020-12-31 | -24.38% |
| 2019-12-31 | -32.74% |
| 2018-12-31 | -18.10% |
| 2017-12-31 | -61.12% |
| 2016-12-31 | -74.96% |
